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Abstract
Background: National mapping of lymphatic filariasis (LF) was conducted using Immunochromatographic tests
(ICT) in 2005 to determine endemicity and geographic spread of the disease. A baseline microfilaria survey was
then conducted to determine LF prevalence and microfilaria intensity.
Methods: In 2005 1,982 persons of 15 years and over from 14 health districts were selected and fingertip blood
samples were tested with ICT cards. In 2007-8 blood samples were taken between 10 p.m. and 2 a.m. and
examined for microfilaria (mf) from 9,288 persons from 16 sentinel sites representing each district and 2 additional
sites for districts with populations over 500,000 (Bo and Kenema).
Results: The overall LF prevalence by ICT cards was 21% (males 28%, females 15%). All districts had a prevalence
of Wuchereria bancrofti antigen > 1%. Distribution of LF prevalence showed a strong spatial correlation pattern
with high prevalence in a large area in the northeast gradually decreasing to a relatively low prevalence in the
southwest coast. High prevalence was found in the northeast, Bombali (52%), Koinadugu (46%), Tonkolili (37%) and
Kono (30%). Low prevalence was found in the southwest, Bonthe (3%) and Pujehun (4%). The mf prevalence was
higher in the northeast: Bombali, 6.7%, Koinadugu 5.7%, Port Loko 4.4% and Kono 2.4%. Overall there was a
significant difference in mf prevalence by gender: males 2.9%, females 1.8% (p = 0.0002) and within districts in
Kailahun, Kono, Port Loko, Moyamba and Koinadugu (all p < 0.05). The mf prevalence was higher in people > 20
years (2.5%) than in people ≤ 20 years (1.7%) (p = 0.043). The overall arithmetic mean mf density was 50.30 mf/ml
among mf-positive individuals and 1.19 mf/ml in the population examined which varied significantly between
districts.
Conclusions: The ICT results showed that LF was endemic nationwide and that preventive chemotherapy (PCT)
was justified across the country. Both the ICT and microfilaraemia surveys found that prevalence was greater in
males than females. The increase in microfilaraemia prevalence by age was evident when grouped as ≤ 20 versus
> 20 years demonstrating early exposure. Baseline LF microfilaria load will be used to monitor PCT program
progress.
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Background
Lymphatic filariasis (LF) is a chronic, debilitating disease
that affects people in tropical and subtropical areas of
Asia, Africa, the Western Pacific and some areas of the
Americas caused by the parasites Wuchereria bancrofti
or Brugia malayi and B. timori, transmitted by Culex,
Anopheles and other mosquitoes [1-4]. An estimated
90% of all LF cases worldwide and all cases in Africa are
infections with the parasite W. bancrofti. The main vec-
tors in West Africa are the Anopheles mosquitoes [5].
Over 120 million people in over 80 countries worldwide
in the tropics and subtropics and over 40 million people
in Africa are infected with the parasite [6,7]. Bancroftian
filariasis, which is prevalent in Africa, is endemic in
rural as well as urban communities thriving within poor
communities [5,8,9].
LF has a wide range of clinical manifestation from
acute attacks of filarial fever, chronic conditions such as
hydroceles, lymphoedema, elephantiasis of limbs, and
enlarged breasts, to kidney damage, thus causing great
morbidity and disability for those affected [10]. Filariasis
is one of the most common causes of permanent dis-
ability worldwide creating the highest disease burden in
terms of DALYs among tropical diseases [7]. Those
affected also suffer psychosocial stigmatization and eco-
nomic suffering as it can lead to job loss or inability to
work. The disease is therefore a major cause of poverty
as it creates economic burden for those affected, their
dependants, their communities and the country as a
whole [8,9,11-13]. In 1993 the International Task Force
on Disease Eradication identified LF as one of six dis-
eases that could be eradicated, which led the World
Health Assembly in 1997 to pass resolution WHA 50.29
calling for the elimination of LF as a public health pro-
blem in the world by 2020. In 1998, the Global Alliance
to Eliminate LF was formed to support LF elimination
programmes in endemic countries and World Health
Organization (WHO) launched a Global Programme for
the Elimination of LF as a result [2,3,13-15].
Circulating microfilariae (mf) are responsible for
transmission, therefore transmission can be broken/
interrupted by reducing the number of people with
microfilaraemia within affected communities through
annual mass drug administration (MDA) for 4-6 years
to ≥ 80% of the entire at-risk population which can
reduce mf to zero or close to zero [16,17]. Before MDA
is started in a country, implementation units to be tar-
geted should be determined through a rapid assessment
study and also baseline data on LF mf level should be
obtained to monitor effectiveness of MDA. There are
already countries that have succeeded in eliminating the
disease (Cape Verde, China, Costa Rica, Solomon
Islands, South Korea, Suriname, and Trinidad and
Tobago) using a combination of strategies that include
vector control and single annual doses of 2-drug treat-
ments (albendazole together with ivermectin or diethyl-
carbamazine) [16,17]. The current preferred strategy for
LF elimination recommended by WHO is the preventive
chemotherapy using the available drugs [18,19]. The glo-
bal LF elimination programme has been strengthened by
donation of albendazole by GlaxoSmithKline and con-
tinued donation of ivermectin by Merck & Co [20].
In Sierra Leone, reports from health facilities indicated
endemicity of LF in all districts, and in 1996, a study in
Moyamba district using the thick blood film method
showed mf prevalence: 10.2% with 36.5% clinical mani-
festation (26.6% hydroceles and 9.4% lymphoedema/ele-
phantiasis of the lower extremities) [21]. In 2004, a
country profile of communicable diseases in Sierra
Leone developed by WHO, quoting an anonymous 1999
study in 55 sites including the capital Freetown, showed
that 14.5% of people tested for circulating filarial antigen
of W. bancrofti were positive [22]. The Northern Pro-
vince had the highest prevalence (19.6%), followed by
Western Area (12.8%), Eastern Province (12.7%) and
Southern Province (10.9%) [22]. Infection was noted in
children, and this indicated ongoing transmission and
infections acquired early in life.
In preparation for the national LF elimination pro-
gramme, national mapping was conducted in 2005 using
immunochromatographic test (ICT) cards. The national
LF elimination programme started when the Ministry of
Health and Sanitation (MoHS), Sierra Leone in consul-
tation with WHO decided to conduct the integrated
management of onchocerciasis, LF, schistosomiasis, soil-
transmitted helminthes and trachoma, and the existing
National Onchocerciasis Control Programme became
National Neglected Tropical Disease Control Pro-
gramme (NTDCP) in 2006 [23]. Based on the mapping
results, the implementation units (districts) for LF MDA
were determined and national baseline data on mf level
were collected pre-MDA. The current paper presents
the distribution and the level of infection of LF in Sierra
Leone which formed the base for the national LF elimi-
nation programme.
Methods
Ethics statement
The studies were conducted by the National NTDCP of
the MoHS, Sierra Leone. Ethical approval for data col-
lection was obtained from the Ethics Committee of the
MoHS and upon arrival at the randomly selected com-
munities the investigating team met with the commu-
nity leaders and explained the nature of their work. All
participants aged 15 years or above in each site were eli-
gible for inclusion without discrimination on gender,
Koroma et al. Parasites & Vectors 2012, 5:10
http://www.parasitesandvectors.com/content/5/1/10
Page 2 of 8
social status, religion or ethnicity. People participated in
the studies after informed consent was verbally obtained
and recorded by the team leader, as literacy rates are
low in Sierra Leone. Data collection was conducted such
that participants remained anonymous during data entry
and analysis. No individual identity can be revealed
upon publication.
National mapping of LF with ICT cards in 2005
Although previous studies and clinical records indicated
that LF was prevalent particularly in the north, detailed
data on distribution and level of risk throughout the
country was not available, and all districts including the
Rural Western Area both Rural (RWA) and Urban Wes-
tern Area (UWA) were included in the mapping. Thirty-
four (34) communities were randomly selected from all
districts in consultation with WHO/AFRO with each
district having at least one community selected. Partici-
pants who were 15 years of age or above were selected
for the antigenaemia study using ICT cards [24]. During
the survey ICT cards were kept overnight at 8°C in dis-
trict cold rooms for the expanded programme on immu-
nization and during the day the cards were transported
in cold boxes and vaccine carriers with ice packs. The
left index finger was pricked with a sterile lancet after
cleaning with cotton wool soaked with spirit and 100 μl
blood collected and applied straight to the ICT cards.
The survey teams were trained to read the results of the
ICT cards at exactly 10 minutes after application,
according to the manufacturer’s instructions. No late
reading of ICT cards was reported by the survey teams.
Due to limited resources and the high sensitivity and
specificity of the ICT [25,26], fifty (50) persons were
sampled in each randomly selected community and if a
positive case was identified the sampling was complete
and the teams moved on to the next site. If in the first
50 samples there was no positive case found, a further
50 persons were sampled bringing the total to 100 per
site [26]. Training of technicians in the use of the ICT
cards to detect W. bancrofti antigen and data recording
took place in Makeni and York Village, RWA. Three
teams of three technicians (2 for specimen collection
and 1 for reading and recording of results) worked with
a village volunteer (usually a school teacher) who served
as registrar. Data included name, sex, village, chiefdom
and district. A total of 1,982 people were tested; males
904 (45.6%) and females 1,078 (54.4%).
Baseline microfilaraemia data collection before MDA
Sampling was conducted in accordance with WHO
guidelines [26] of two sentinel sites per implementation
unit (district for Sierra Leone) with a population of one
million people. Ten of the fourteen health districts of
Sierra Leone have a population below 500,000 and one
sentinel site per district was selected representing a
population ≤ 500,000. One sentinel site each was
selected for RWA (232,294) and UWA (901,953). Bo
district (Bo Town: Bo District, 222,561: 347,610) and
Kenema district (Kenema Town: Kenema District,
188,869: 377,067) had population above 500,000 and
two sentinel sites were selected in these two districts,
making a total of 16 sites. Communities/villages that
showed the highest ICT prevalence in each district in
2005 were selected as mf sentinel sites [26]. The survey
was performed in two phases according to funding avail-
ability: Bombali, Koinadugu, Kambia, Kono, Kailahun
and Pujehun in 2007 and Tonkolili, Port Loko, Kenema,
Bonthe, Moyamba, Bo, RWA and UWA in 2008. Pre-
sensitization was carried out before the survey in each
site. Five hundred participants of 15 years of age or
above were recruited per site. In sites with less than 500
people selected, extra participants were recruited in
neighbouring villages. To ensure the standardization of
activities and data, two day practical training was per-
formed before the study started for all technicians. Fin-
gertip blood was collected between 10 p.m. and 2 a.m.
from each volunteer. A 60 μl blood sample was col-
lected, smeared gently and uniformly in a circular shape
and allowed to air dry at room temperature for 12-24
hours. The following day the dried smear was dehaemo-
globinized by flooding with distilled water for 3-5 min-
utes, air dried again, fixed with methanol for 30-60
seconds, stained with Giemsa for 10 minutes then exam-
ined for mf under a light microscope by experienced
examiners. Positive findings of mf were recorded and
individual mf density of infection was calculated and
expressed as the number of mf per ml of blood (mf/ml)
[26-29]. A total of 9,288 night blood samples were
examined. The mean age (± standard deviation) of the
subjects examined was 37.7 ± 17.04 years (males: 37.27
± 17.6, females: 38.12 ± 16.5). For quality control, all
positive slides and 10% of the negative slides were pre-
served and examined by an experienced researcher.
Statistical analysis
Results were entered into Epi-Info version 3.5.2 and
analyzed in SPSS (IBM, Version 19). Prevalence of posi-
tive circulating LF antigen or microfilaraemia was calcu-
lated. The 95% confidence intervals (CIs) for prevalence
were calculated using the Wilson score method without
continuity correction [30]. The arithmetic mean mf den-
sity of infection with 95% CIs was calculated using the
total population examined and the positive samples only
[26]. Chi-square test was used to compare the differ-
ences in prevalence and Kruskal-Wallis test was used to
compare the differences in mf density. Correlation ana-
lysis was conducted for the two sets of data (ICT and
microfilaraemia prevalences) and the significance of the
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correlation tested [31]. The coordinates of each sample
site were recorded using hand-held units of global posi-
tioning system (site coordinates available upon request).
Spatial analysis of the LF antigenaemia prevalence (ICT
card data) was conducted using the kriging method in
the Geostatistical Analyst Extension of ArcGIS version
10 (ESRI, Redlands, USA). Spatially smoothed contour
maps of the interpolated prevalence of antigenaemia and
the predictive probability for the ICT prevalence of
greater than 1% were produced [32].
Results
Distribution of lymphatic filariasis in Sierra Leone
Table 1 summarizes the results of the survey using ICT
cards for each district. All the districts of Sierra Leone
were found to be endemic for LF with a prevalence of
ICT positive tests ≥ 1%. Point prevalence for each sur-
vey site was shown in Figure 1. Among 34 sites sur-
veyed, only one site in Bonthe district was shown to be
negative. The median prevalence across the 34 sites was
20% ranging from 0% to 68% (inter-quantile range: 11.7-
31%). Overall ICT positive prevalence was 20.8%. High
Table 1 Crude LF prevalence with antigen detection and microfilaraemia tests by district, sex and age group in Sierra
Leone
No of persons
tested by ICT
cards
Percentage prevalence
of antigen positives
(95% CI)
No of persons
examined for
Mf
Percentage prevalence
of Mf positives (95%
CI)
Population Mf
density (mf/ml)
(95% CI)
Positive-only Mf
density (mf/ml)
(95% CI)
Overall 1982 20.8 (19.1 - 22.7) 9288 2.4 (2.1 - 2.7) 1.19 (0.90 - 1.48) 50.3 (39.89 - 60.71)
By district
Bo 173 15.0 (10.5 - 21.1) 1005 2.0 (1.3 - 3.1) 1.97 (0.84 - 3.11) 99.17 (58.32 - 140.01)
Bombali 150 52 (44.1 - 59.8) 830 6.9 (5.3 - 8.8) 1.93 (1.28 - 2.57) 28.07 (21.70 - 34.44)
Bonthe 160 3.1 (1.3 - 7.1) 504 1.2 (0.6 - 2.6) 0.83 (0.02 - 1.63) 69.44 (13.68 - 125.21)
Kailahun 110 19.1 (12.8 - 27.4) 624 2.6 (1.6 - 4.1) 2.08 (0.00 - 4.89) 81.25 (0.00 - 195.58)
Kambia 110 15.5 (9.9 - 23.4) 619 2.1 (1.2 - 3.6) 0.97 (0.23 - 1.71) 46.15 (17.04 - 75.27)
Kenema 180 13.3 (9.1 - 19.1) 1016 0.6 (0.3 - 1.3) 0.34 (0.00 - 0.70) 58.33 (4.42 - 112.24)
Koinadugu 200 46 (39.2 - 52.9) 636 5.7 (4.1 - 7.7) 1.99 (0.95 - 3.04) 35.19 (19.83 - 50.54)
Kono 100 30 (21.9 - 39.6) 875 2.4 (1.6 - 3.6) 1.11 (0.37 - 1.84) 46.03 (20.09 - 71.97)
Moyamba 200 10.5 (7.0 - 15.5) 500 1 (0.4 - 2.3) 0.67 (0.00 - 1.36) 66.67 (6.33 - 127.00)
Port Loko 210 20.5 (15.6 - 26.4) 500 4.4 (2.9 - 6.6) 3.53 (1.48 - 5.59) 80.30 (44.49 - 116.12)
Pujehun 160 4.4 (2.1 - 8.8) 624 0 (0 - 0.6) - -
Tonkolili 100 37 (28.2 - 46.8) 500 2.4 (1.4 - 4.2) 0.63 (0.24 - 1.03) 26.39 (17.99 - 34.79)
WA Rural 69 7.3 (3.1 - 15.9) 500 1.2 (0.6 - 2.6) 0.33 (0.01 - 0.65) 27.78 (6.60 - 48.96)
WA Urban 60 11.7 (5.8 - 22.2) 555 0 (0 - 0.7) - -
By sex
Male 904 27.5 (24.7 - 30.6) 4335 3.0 (2.6 - 3.6) 1.66 (1.11 - 2.20) 54.42 (38.81 - 70.02)
Female 1078 15.2 (13.2 - 17.5) 4953 1.8 (1.4 - 2.2) 0.78 (0.52 - 1.04)) 44.13 (32.50 - 55.76)
By age
group
(yrs)
15-20 - - 1873 1.8 (1.3 - 2.5) 0.78 (0.38 - 1.19) 44.44 (26.37 - 62.52)
21-30 - - 2019 2.6 (2.0 - 3.4) 1.77 (0.73 - 2.80) 68.59 (31.79 - 105.39)
31-40 - - 1830 2.4 (1.8 - 3.2) 1.01 (0.55 - 1.47) 43.02 (27.55 - 58.50)
41-50 - - 1404 3.4 (2.5 - 4.4) 1.60 (0.94 - 2.27) 47.87 (32.75 - 62.99)
> 50 - - 2162 2.1 (1.6 - 2.8) 0.89 (0.49 - 1.30) 42.96 (27.40 - 58.53)
Figure 1 Geographical distribution of lymphatic filariasis point
prevalence by circulating antigen detection with ICT cards
according to survey locations in Sierra Leone.
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prevalence was found in the northeast part of the coun-
try (Bombali 52%, Koinadugu 46%, Tonkolili 37% and
Kono 30%). Relatively low prevalence was found in the
southwest coastal districts (Bonthe 3.1% and Pujehun
4.4%).
There were significantly more positive ICT tests in
males (27.54%, 95% confidence interval (CI): 24.7-30.6%)
than in females (15.2%, 95% CI: 13.2-17.5%) (p <
0.00001). Detailed analysis of prevalence among different
age groups was not carried out as detailed age informa-
tion was not recorded for the ICT card survey.
Microfilaraemia prevalence and density
Overall 9,288 night blood samples, male 4,335 (46.7%)
and female 4,953 (53.3%), were examined for mf as
shown in Table 1. There were less than 5% false posi-
tives and no false negative slides. All positive slides were
reexamined and 3 were redefined as artifacts. No mf of
Mansonella perstans was detected.
In total, 220 persons (2.4%, 95% CI: 2.1-2.7%) had a
positive blood smear and there was significantly higher
mf prevalence in males 3.0% (95% CI: 2.6-3.6%) versus
females 1.8% (95% CI: 1.4-2.2%) (p = 0.0002). Age distri-
bution of the mf prevalence is also shown in Table 1.
There was a significant difference in mf prevalence
among age groups with higher prevalence in persons of
41-50 years (p = 0.041).
The point prevalence of microfilaraemia for each site
is shown in Figure 2. There was a significant correlation
between the mf prevalence and the ICT card prevalence
(r = 0.86, p < 0.05). In line with the ICT results, the mf
prevalence (95% CI) was higher in the northeast part of
the country: Bombali, 6.9% (5.3-8.8%), Koinadugu 5.7%
(4.1-7.7%), Port Loko 4.4% (2.9-6.6%), Kailahun 2.6%
(1.6-4.1%) and Kono 2.4% (1.6-3.6%). No mf was found
in persons examined in the UWA and Pujehun.
The overall arithmetic mean mf density was 50.30 mf/
ml (95% CI: 39.89-60.71 mf/ml) among mf-positive indi-
viduals, and 1.19 mf/ml (95% CI: 0.90-1.48 mf/ml) in
the population examined (Table 1). There was signifi-
cantly higher mf density in the male population than in
the female population (p < 0.0001). There was also a
significant difference in mf density among age groups in
the total population examined (p = 0.041). There was
no significant difference in mf density by sex or age
groups of infected persons (p > 0.1).
Spatial prediction of LF distribution
The spatial analysis of the ICT card data showed a
strong spatial correlation pattern as the semi-variance in
prevalence data in relation to the distance between sur-
vey sites (Figure not shown). The predicted spatial dis-
tribution of LF by kriging is shown in Figure 3. This
shows a widespread distribution of LF prevalence with a
clear geographical distribution pattern in Sierra Leone:
high (> 40%) in a large area spanning the northeast of
the country with two clusters of predicted prevalence of
over 50%, gradually decreasing towards the southwest,
and ending low (< 5%) in the coastal part of Bonthe and
Pujehun districts. Figure 4 shows the predicted probabil-
ity of the LF prevalence being over 1%, which shows
Figure 2 Geographical distribution of lymphatic filariasis point
prevalence by mf detection and point mf density according to
survey locations in Sierra Leone.
Figure 3 Spatially smoothed contour map of predicted LF
prevalence by ICT cards in Sierra Leone.
Koroma et al. Parasites & Vectors 2012, 5:10
http://www.parasitesandvectors.com/content/5/1/10
Page 5 of 8
high probability throughout the country with only two
small clusters of relatively low probability (< 50%) in
Bonthe and Moyamba.
Discussion
All districts in Sierra Leone were endemic with LF and
qualified for MDA. Distribution of LF prevalence
showed a strong spatial correlation pattern with high
prevalence in a large area in the northeast gradually
decreasing to relatively low prevalence in the southwest
coast. ICT results showed two distinct patterns: males
were more infected than females and districts in the
northeast part of the country had a higher prevalence
than other districts. The ICT results obtained in this
study were higher than in 2004 but the same pattern of
a higher prevalence for circulating filarial antigen in the
north than all other regions was repeated [22]. Three
distinct patterns were also noted in the microfilaraemia
survey: microfilaraemia was higher in males (3.0%) ver-
sus females (1.8%), increased with age in the population
peaking at 41-50 years, and showed higher prevalence in
the northeast than in other parts of the country. In two
districts (UWA and Pujehun), microfilaraemia was not
identified among the subjects examined, even though
ICT prevalence was 11.7% and 4.4% respectively.
The mf prevalence was lower than that reported in
1996 but that study was conducted in an area with
clearly visible signs of the disease to highlight the ser-
iousness of the problem [21]. There were many such
areas in the districts where LF signs were clearly visible
among the population but in this study the sites were
randomly selected to avoid bias, therefore the results of
this study were more representative of the mf preva-
lence in the district population. The results acquired in
this study on mf prevalence and mf density/intensity
will form the basis for monitoring and evaluation of the
effectiveness of MDA in interrupting LF transmission in
each district.
Similar patterns are noted for both studies in geogra-
phical and sex distribution of the disease, which further
strengthens the notion that these results are representa-
tive of the actual national picture. The ICT positive pre-
valence was nine times greater than the mf prevalence.
Several authors have reported that ICT positive preva-
lence, which detects antigen released by adult W. ban-
crofti, can be 3-5 times higher than mf prevalence.
People can be infected with the disease and still be ami-
crofilaraemic, which may explain the zero mf prevalence
in UWA and Pujehun district in these studies [27,33,34].
Previous studies demonstrated the impact of long-
term treatment with ivermectin alone for onchocerciasis
control on LF prevalence and transmission, which
showed that in villages treated for many years with iver-
mectin, LF microfilaraemia prevalence and intensity
were significantly lower than in untreated villages
[35,36]. Antigenaemia rates were significantly higher
than microfilaraemia rates generally [35,36]. Onchocer-
ciasis was endemic in 12 out of the 14 health districts in
Sierra Leone [23]. Community based treatment with
ivermectin for the control of onchocerciasis in Sierra
Leone started in the late 1980s but did not reach full
geographical coverage due to insecurity at the beginning
of the civil war in 1991 and were subsequently sus-
pended in 1994. In 2003 community-directed treatment
with ivermectin (CDTI) was introduced but therapeutic
coverage was low in the post conflict setting. In 2005
the National Onchocerciasis Control Program (NOCP)
was reorganized and therapeutic coverage reached the
prerequisite ≥ 65% and has been maintained in all ende-
mic districts since [23]. The relatively low microfilarae-
mia rates in our study and the difference between
antigenaemia rates and microfilaraemia rates may have
been due to the ivermectin treatment for onchocerciasis
control in Sierra Leone before the surveys were
conducted.
The current results are in line with other studies that
males have higher prevalence than females for circulat-
ing filarial antigen as well as for microfilaraemia
[12,37,38]. The most probable reason for this is that
males spend more time exposed to the bites of mosqui-
toes. The distribution of mf prevalence increasing with
age shown in this study is in line with results of many
other studies [9,12,33,37,38]. This emphasizes the
Figure 4 Spatially smoothed contour map of the predicted
probability that the prevalence of LF antigenaemia exceeds
1%.
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socioeconomic impact of the disease as the age groups
affected most are the major workforce in the villages. In
Sierra Leone an estimated 70% of adults are farmers
[39], and disability from LF incapacitates those affected
and increases poverty, which is a cause for concern as
the country is among the poorest in the world and
demands appropriate attention for elimination of the
disease. It has been suggested that adults could be more
exposed to mosquito bites because of higher relative
heat, more carbon dioxide output or simply because
they have relatively greater surface area that can be bit-
ten by mosquitoes [38]. Similar studies on antigenaemia
and microfilaraemia for W. bancrofti have been con-
ducted in other countries that reflected similar gender
and age pattern as our studies [40-42].
There are certain limitations for the current studies.
Firstly, children below 15 years were not selected for
circulating filarial antigen and for microfilaria according
to the WHO guidelines [24]. The WHO profile for LF
in Sierra Leone in 2004 indicated that children were
infected and that the infection could be acquired early
in life [22]. It has been suggested that excluding children
below 15 years could bias the studies towards older peo-
ple and since it is common knowledge that filariasis
infection increases with age, the prevalence might have
been overestimated for the general population compared
to other studies that used population based sampling
methodology [33]. While this may have been true in this
study, considering the overall global objective is LF
elimination, such slight overestimation of LF prevalence
due to the age bias should not have made much differ-
ence in terms of MDA decision in Sierra Leone. Sec-
ondly, it is recommended that ICT cards be stored at or
around 8°C [13]. Although efforts were made to keep
the cards in cold box during the field work, the rela-
tively poor field conditions in the remote villages may
have made it difficult to keep the box cold at all time.
In such field conditions, reading every card within the
time limit may not have been guaranteed. This may in
part explain the higher ICT positive prevalence (nine
times greater than the mf prevalence) in the current stu-
dies than in other studies [27,33,34]. However, taking
both ICT and mf positive prevalence together, there is a
strong correlation between the results of the two surveys
for the 14 health districts as shown through correlation
analysis. Therefore, the results can be considered to be
representative of the true LF endemic situation in Sierra
Leone.
Based on the information provided by these studies,
the national NTDCP started LF MDA in 2007 [23].
Four rounds of MDA with albendazole and ivermectin
have been delivered in 6 districts, three rounds in 7
districts RWA and two rounds in the UWA [43]. The
mid-term impact assessment is now being conducted
at the sentinel sites plus several hot spots with local
knowledge of high occurrence of LF morbidity using
blood smears for mf detection. It is hoped that the
assessment results will provide tools to evaluate the
impact of the MDA and to adjust the course of MDA
if necessary.
Conclusion
LF mapping using ICT cards was successfully conducted
in 2005 in all districts of Sierra Leone which showed
that all districts were endemic for LF and qualified for
MDA. Baseline data collection with night blood smear
was conducted in 2007-08 before MDA, which provided
baseline values for mf prevalence and mf density and
confirmed LF endemic status determined by ICT card
survey across the country. These surveys provided tools
for the NTDCP to design and implement MDA and
provided the basis for future monitoring and evaluation
of the national LF elimination programme.
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